Endpoints News
Lilly is exploring the psychedelic ibogaine Read in browser
Endpoints News
Thank you for reading, Test Researcher!
basic
UPGRADE
M T W Th Fri
16 October, 2026
ENDPOINTS at #JPM27 - BIOPHARMA'S NEW BALANCE OF POWER
Biopharma's balance of power is shifting, and in January, Endpoints journalists will press the people at the center of it on who's rising, who's falling and where the industry may land by the end of the decade. Join us at #JPM27 for exclusive conversations and interviews you won't get anywhere else. Save $200 on your all-access pass with Early Bird, or join us virtually for free.
presented by Parexel
Greater em­pa­thy, greater ef­fi­cien­cy: How pa­tient-first clin­i­cal de­vel­op­ment ben­e­fits all of us
top stories
1. Chinese government pursues export ban on select biopharma tech
2. Lilly wants to study and improve the psychedelic ibogaine, its neuro leader says
3. Novartis scraps Fabhalta study in lupus nephritis
4.
news briefing
FDA considers interim access for compounded peptides; Enspryng's label expansion
5. City Therapeutics lands $200M IPO as it builds an Alnylam 2.0 in RNAi field
6. Estuary debuts with $103M to develop kidney disease gene therapies
7.
peer review
Ex-Genentech scientist joins Ira Mellman at Medici; Intellia poaches CMO from Scholar Rock
more stories
• 
Karen Weintraub
.

The Chinese government issued draft export restrictions on a wide range of technologies, including cell and gene therapy platforms. This comes as the US contemplates outbound investment restrictions of its own, as Max Bayer and Robert Postings report.
.
Karen Weintraub
Deputy Editor, Endpoints News
Endpoints webinars
Nov 12
12:30 pm ET
From data to diagnostic: How AI is powering biomarker discovery
Guardant Health
Nov 03
11:30 am ET
Trust, not autonomy: Deploying agentic AI in GxP environments
Katalyze
Nov 04
11:00 am ET
Cutting through the noise: How biopharma is actually using AI to scale oncology research
Flatiron Health
Nov 19
12:30 pm ET
Is your drug working? Earlier insights with molecular response monitoring and RWD
Natera
Oct 20
11:00 am ET
Intelligent oversight and orchestration: How mission control is redefining R&D decision-making
ZS
Oct 21
11:00 am ET
From prediction to decision: Digital twins and predictive modeling in clinical development
Flatiron
Oct 22
11:00 am ET
A new model for clinical research – Expanding community trial access
Parexel
Oct 28
10:30 am ET
The evolution of MRD: From molecular detection to clinical decisions
ABBOTT
1
by Max Bayer, Robert Postings